Details of proposed European PFAS ban released Today, the European Chemicals Agency (ECHA) published details of a proposed ban on the production, use, sale and import of some 10,000 per- and polyfluoroalkyl substances (PFAS).
New risk limits for 18 pesticides in surface water Evidence suggests that existing standards for some of these substances do not sufficiently protect the ecosystem. For others, no standards exist yet or the existing standards are outdated. If these
COVID-19 vaccine uptake related to neighbourhood demographics COVID-19 vaccine uptake was lower in neighbourhoods that had proportionately higher percentages of residents from a non-Western migration background and residents who were more likely to vote for right-wing Christian and right-wing conservative political parties. iStock
RIVM and TNO describe impact of future developments on occupational health and safety RIVM and the Netherlands Organisation for Applied Scientific Research (TNO) have investigated the potential impact of developments in the next 20 years on occupational health and safety. How will artificial intelligence affect safety at work? iStock
Provisional figures on participation in the National Immunisation Programme According to RIVM’s registration system, at least 90% of babies have been vaccinated against mumps, measles and rubella (MMR).
RIVM to research safe design for new nanoparticles RIVM will be working alongside a consortium of 23 international partners on a safe design for ‘new’ nanoparticles.
Breast milk as indicator of environmental pollutants The 6th worldwide study into Persistent Organic Pollutants (POPs) in breast milk is about to commence.
The National Immunisation Programme in the Netherlands: Developments in 2013 Annually RIVM provides an overview of key events and developments in the National Immunisation Programme (NIP).
New RIVM-method used to detect influenza A (H7H9) population immunity The level of immunity to the recently circulating H7N9 influenza virus in an urban and rural population in Vietnam is very low, according to the first population level study to examine human immuni